KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Shares Outstanding (Diluted Average) (2016 - 2025)

Biogen (BIIB) has 17 years of Shares Outstanding (Diluted Average) data on record, last reported at $147.1 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 0.82% year-over-year to $147.1 million; the TTM value through Dec 2025 reached $147.1 million, up 0.82%, while the annual FY2025 figure was $147.1 million, 0.82% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $147.1 million in Q4 2025 per BIIB's latest filing, roughly flat from $147.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $152.3 million in Q1 2021 and bottomed at $145.2 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $147.1 million, with a median of $146.2 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): decreased 12.02% in 2021, then rose 0.82% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $149.6 million in 2021, then decreased by 2.41% to $146.0 million in 2022, then fell by 0.27% to $145.6 million in 2023, then grew by 0.21% to $145.9 million in 2024, then increased by 0.82% to $147.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $147.1 million in Q4 2025, $147.1 million in Q3 2025, and $146.7 million in Q2 2025.